68997-45-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-MORPHOLINOETHOXY)BENZALDEHYDE serves as a crucial building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of novel drugs, making it valuable in medicinal chemistry and drug discovery.
Used in Organic Synthesis:
In the realm of organic chemistry, 2-(2-MORPHOLINOETHOXY)BENZALDEHYDE is utilized as a reagent. Its versatility in forming different types of chemical bonds and its compatibility with numerous reaction conditions make it an important tool for advancing chemical research and development.

InChI:InChI=1/C13H17NO3/c15-11-12-3-1-2-4-13(12)17-10-7-14-5-8-16-9-6-14/h1-4,11H,5-10H2

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 90-02-8 salicylaldehyde 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Downstream Products

• 88137-02-4 (E)-3-[2-(2-Morpholin-4-yl-ethoxy)-phenyl]-2-thiophen-2-yl-acrylonitrile; hydrochloride 
• 88137-22-8 (Z)-2-(1,2-benzisoxazol-3-yl)-3-<2-(2-morpholinoethoxy)phenyl>acrylonitrile 
• 88137-16-0 3-{(E)-2-[2-(2-Morpholin-4-yl-ethoxy)-phenyl]-vinyl}-benzo[d]isoxazole; hydrochloride 
• 88137-48-8 3-{(E)-2-[2-(2-Morpholin-4-yl-ethoxy)-phenyl]-vinyl}-benzo[d]isoxazole 
• 82625-23-8 4-{2-[2-((Z)-2-Benzo[d]isoxazol-3-yl-2-cyano-vinyl)-phenoxy]-ethyl}-4-methyl-morpholin-4-ium; iodide 
• 68997-48-8 4-Chloro-N-[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)benzamide, hydrochloride salt 
• 68997-47-7 [2-(2-morpholin-4-yl-ethoxy)-benzyl]-phenethyl-amine 
• 88137-34-2 (Z)-2-Benzo[d]isothiazol-3-yl-3-[2-(2-morpholin-4-yl-ethoxy)-phenyl]-acrylonitrile 
• 88136-94-1 2-(1,2-benzisothiazol-3-yl)-3-<2-(2-morpholinoethoxy)phenyl>acrylonitrile hydrochloride 
• 112562-97-7 2-[2-(2-Morpholin-4-yl-ethoxy)-phenyl]-thiazolidine-3-carbothioic acid methylamide; hydrochloride 

Relevant academic research and scientific papers

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Substituted amides and sulfonamides containing a heterocyclic group having antiinflammatory activity

Compounds having the formula STR1 wherein R1 is alkyl, cycloalkyl or aryl; R2 is acyl or sulfonyl; R3 is a nitrogen containing heterocyclic group; A1 is a saturated bond or an alkylene group having 1 to 4 carbon